阿尔茨海默病患者对胆碱酯酶抑制剂的依从性、持续性和延续性
Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease.
作者信息
Le Couteur David G, Robinson Maxine, Leverton Ann, Creasey Helen, Waite Louise, Atkins Kerry, McLachlan Andrew J
机构信息
Centre for Education and Research on Ageing, University of Sydney and Concord RG Hospital, Sydney, New South Wales, Australia.
出版信息
Australas J Ageing. 2012 Sep;31(3):164-9. doi: 10.1111/j.1741-6612.2011.00564.x. Epub 2011 Sep 4.
AIM
To determine adherence, persistence and continuation beyond 6 months with cholinesterase inhibitors in Australians with Alzheimer's disease.
METHODS
Adherence and persistence with cholinesterase inhibitors were assessed by data linkage using the Pharmaceutical Benefits Scheme (PBS) Authority database and other health databases.
RESULTS
Over 18 000 people commenced cholinesterase inhibitors during 2004. Adherence was 79.4% while the medication possession ratio was 0.88. Some 70.3% of people filled all six scripts for the initial trial period of therapy. Some 57.3% of evaluable patients accessed funding beyond six prescriptions, indicating that their clinicians had declared that there was a two-point or more greater improvement in the Mini-Mental State Examination. Despite the high rate of continuation beyond 6 months, the rates of institutionalisation and death were no different to those reported in clinical trials.
CONCLUSIONS
Persistence and adherence with cholinesterase inhibitors was reasonable once treatment was established. There was an unexpectedly high continuation rate beyond six prescriptions.
目的
确定澳大利亚阿尔茨海默病患者使用胆碱酯酶抑制剂的依从性、持续性以及6个月后的持续用药情况。
方法
通过使用药品福利计划（PBS）管理数据库和其他健康数据库进行数据关联，评估胆碱酯酶抑制剂的依从性和持续性。
结果
2004年期间，超过18000人开始使用胆碱酯酶抑制剂。依从性为79.4%，而药物持有率为0.88。约70.3%的人在初始治疗试验期内用完了所有六个疗程的药物。约57.3%的可评估患者在六个处方之后仍获得了资助，这表明他们的临床医生宣称其简易精神状态检查表的得分提高了两分或更多。尽管6个月后的持续用药率很高，但住院率和死亡率与临床试验报告的并无差异。
结论
一旦确立治疗，胆碱酯酶抑制剂的持续性和依从性是合理的。六个处方之后的持续用药率出乎意料地高。
Zotero 插件